FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
Elio Adib, Talal El‐Zarif, Rohit K. Jain and 10 more
BJUI Compass · 2022
doi:10.1002/bco2.125 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
GAs on the activity of EV and the optimal sequencing of EV and erdafitinib in mUC.
Abstract licence: CC BY
References8
8 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.